TW200808327A - Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma - Google Patents

Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma Download PDF

Info

Publication number
TW200808327A
TW200808327A TW096114301A TW96114301A TW200808327A TW 200808327 A TW200808327 A TW 200808327A TW 096114301 A TW096114301 A TW 096114301A TW 96114301 A TW96114301 A TW 96114301A TW 200808327 A TW200808327 A TW 200808327A
Authority
TW
Taiwan
Prior art keywords
dose
administered
thymosin
use according
day
Prior art date
Application number
TW096114301A
Other languages
English (en)
Chinese (zh)
Inventor
Paolo Carminati
Roberto Camerini
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/424,475 external-priority patent/US20070292392A1/en
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of TW200808327A publication Critical patent/TW200808327A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/32—Thymopoietins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW096114301A 2006-06-15 2007-04-23 Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma TW200808327A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/424,475 US20070292392A1 (en) 2006-06-15 2006-06-15 Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
US11/734,592 US8017129B2 (en) 2006-06-15 2007-04-12 Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma

Publications (1)

Publication Number Publication Date
TW200808327A true TW200808327A (en) 2008-02-16

Family

ID=38323947

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096114301A TW200808327A (en) 2006-06-15 2007-04-23 Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma

Country Status (14)

Country Link
US (2) US8017129B2 (enExample)
EP (1) EP2032153A1 (enExample)
JP (1) JP2009539916A (enExample)
KR (1) KR20090020646A (enExample)
AR (1) AR061352A1 (enExample)
AU (1) AU2007260145A1 (enExample)
CA (1) CA2652516A1 (enExample)
HR (1) HRP20090010A2 (enExample)
IL (1) IL195955A0 (enExample)
MX (1) MX2008015145A (enExample)
NO (1) NO20090238L (enExample)
RU (1) RU2009101026A (enExample)
TW (1) TW200808327A (enExample)
WO (1) WO2007144218A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7260764B2 (en) * 2002-11-26 2007-08-21 Qualcomm Incorporated Multi-channel transmission and reception with block coding in a communication system
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
CA2708168A1 (en) * 2007-12-14 2009-06-25 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
EP2178093B1 (en) * 2008-10-16 2010-11-24 Orion Tech Anstalt Treatment of liquid wastes containing heavy metals
AU2016217473B2 (en) * 2015-02-09 2021-07-29 Sciclone Pharmaceuticals International (Sg) Pte. Ltd. Thymosin alpha 1 for use in treatment of cystic fibrosis
US9861833B1 (en) * 2017-03-30 2018-01-09 Norman H. Anderson Methods of treating melanoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
US5632983A (en) 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5728707A (en) 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US6462017B1 (en) 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
UA78726C2 (en) 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
UA80957C2 (en) 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
US7101598B2 (en) 2002-05-22 2006-09-05 Om Nova Solutions Inc. Self adhering membrane for roofing applications
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US20080300166A1 (en) 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides

Also Published As

Publication number Publication date
IL195955A0 (en) 2009-09-01
US8029799B2 (en) 2011-10-04
EP2032153A1 (en) 2009-03-11
NO20090238L (no) 2009-03-10
AU2007260145A1 (en) 2007-12-21
RU2009101026A (ru) 2010-07-20
US20070292393A1 (en) 2007-12-20
HRP20090010A2 (en) 2009-02-28
JP2009539916A (ja) 2009-11-19
MX2008015145A (es) 2008-12-15
WO2007144218A1 (en) 2007-12-21
KR20090020646A (ko) 2009-02-26
CA2652516A1 (en) 2007-12-21
US8017129B2 (en) 2011-09-13
AR061352A1 (es) 2008-08-20
US20090186000A1 (en) 2009-07-23

Similar Documents

Publication Publication Date Title
US20070248572A1 (en) Method for treating diseases with omega interferon
US20050112093A1 (en) Combination therapy for HCV infection
TW200808327A (en) Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
AU2002365436A1 (en) Method for treating diseases with omega interferon
JP2007501806A5 (enExample)
Margolin et al. Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma.
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
TW201215401A (en) New treatments of Hepatitis C virus infection
WO2019242688A1 (zh) 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
JP5034944B2 (ja) インターフェロン作用物質の活性増強剤
US12102649B2 (en) Methods and compositions for treating endometriosis
KR102662826B1 (ko) Hbv 감염 치료를 위한 eyp001 및 ifn의 상승작용 효과
US20070292392A1 (en) Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
CN111479572A (zh) Sstr靶向缀合物及其制剂
WO2023093837A1 (zh) 含有铂类药物或者铂类药物共晶的药物组合物及其用途
HK1129840A (en) Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma
CN114259487A (zh) 安五脂素或其药物组合在大肠癌治疗中的应用
JP2024042690A (ja) 非アルコール性脂肪性肝疾患の予防及び／又は治療薬
WO2022023514A1 (en) Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof
HK1084862B (en) Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject
TW200904404A (en) Methods and compositions for contributing to the treatment of cancers
TW201110976A (en) Medicinal agent and method for treatment of intractable chronic hepatitis c